MyFinsight
Home
Blog
About
Contact
Download
Download image
Gross proceeds from
issuance of common stock...
$10,556,500
Proceeds from issuance of
short-term debt, related...
$4,340,000
Net cash provided by
financing activities
$11,032,762
Canceled cashflow
$3,863,738
Net change in cash
$281,336
Canceled cashflow
$10,751,426
Payment of transaction
costs
$2,563,738
Repayment of short-term
debt, related party
$1,300,000
Fair value of common
stock to be issued for...
$7,360,000
Loss on issuance of
common stock in...
-$1,740,000
Prepaid and other
current assets
-$324,609
Accrued interest,
related parties
-$215,903
Change in fair value of
deferred underwriting...
-$196,000
Forgiveness of related party
receivables
$126,275
Depreciation
$1,828
Net cash used in
operating activities
-$9,963,318
Net cash used in
investing activities
-$788,108
Canceled cashflow
$9,964,615
Net loss
-$10,206,517
Loans to iris
acquisition corp
$775,000
Purchases of property and
equipment
$13,108
Accounts payable and
accrued expenses
-$4,035,340
Due from related
party, current
$3,427,000
Forgiveness of unrelated
vendor payables
$2,142,297
Due to related party
-$62,467
Change in the fair value
of warrant...
-$54,312
Back
Back
Cash Flow
source: myfinsight.com
Liminatus Pharma, Inc. (LIMNW)
Liminatus Pharma, Inc. (LIMNW)